Covid-19

#Biologics / Biotechnology #Covid-19 #HIV #In vivo #Therapeutics

Biotech start-up takes another stride toward flu cure 

Covimro, a British biotech start-up, has developed a food-grade compound which has demonstrated its efficacy against the flu virus in an animal model study carried out by A-IR Clinical Research and Pharmidex Pharmaceutical Services.  The in vivo testing analysed Covimro’s antiviral capability against an infection of Influenza A H3N2, a flu variant consistent with… Read More

#News #Start-up Zone

#Clinical trials #Covid-19 #RNA

CV2CoV shows improved immune protection in preclinical study 

CureVac and GSK have published preclinical data investigating immune responses as well as the protective efficacy of CureVac’s first-generation vaccine candidate, CVnCoV, and second-generation vaccine candidate, CV2CoV, against SARS-CoV-2 challenge in non-human primates.   The study, conducted in collaboration with Harvard Medical School, assessed cynomolgus macaques vaccinated… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Third Covid-19 vaccine approved for immunocompromised

Moderna has announced that the U.S. Food and Drug Administration (FDA) has approved an update to the emergency use authorisation for the Moderna Covid-19 vaccine (mRNA-1273) to include a third dose for immunocompromised individuals. The third dose will available to people 18 years of age or older in the United… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Assays #Covid-19 #Drug development

Human studies begin on AI Covid-19 treatment with up to 97% effectiveness

Skymount Medical and Louisiana State University (LSU) have commenced human studies on a unique combination of therapies for Covid-19 patients, known as SM-19. In vitro and in vivo assays conducted by the IIT Research Institute (IITRI) in Chicago showed significant efficacy in reducing viral load of the SARS-Cov-2 virus. The… Read More

#News #Trending News

#Clinical trials #Covid-19 #Data #Funding #Therapeutics

Appili Therapeutics secures $3.5 million in funding

Appili Therapeutics has entered into a $3.5 million convertible security funding agreement with Lind Global Fund. The company intends to use the funding to advance the broader Appili pipeline, including ATI-2307, a novel clinical stage antifungal expected to enter Phase II study in 2022. It will also support the operations… Read More

#News

#Cell therapy #Clinical trials #Covid-19 #Drug development #Drug discovery #Drug targets #Stem cells #Therapeutics

Exploring iPSCs for individual and population health applications

Listen to this article on the DDW Podcast: Brad Hamilton, Founder and Chief Science Officer at GoodCell examines the potential of induced Pluripotent Stem Cells. Across the world, patients suffering from heart failure, donor organ rejection and many other life-altering illnesses are struggling to combat the symptoms of their conditions. What… Read More

#Editor's Choice #Exclusive Content #News

#Clinical trials #Comment #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines

From the editor: Staying focused

The drug discovery sector is amazing, says Lu Rahman. And while we have witnessed that on a global scale throughout the pandemic, we should also recognise some of the equally-outstanding non-Covid related developments that have recently taken place. There is, in my opinion, no better industry to be part of at the… Read More

#Covid-19 #Editor's Choice #Exclusive Content #News #Opinion

#Covid-19 #Immunology / Virology & Vaccines

EC to purchase 200 million doses of Novavax NVX-CoV2373

Novavax has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses of NVX-CoV2373, the company’s recombinant nanoparticle protein-based Covid-19 vaccine candidate with Matrix-M adjuvant. The agreement covers the purchase of up to 100 million doses of the vaccine with the option for… Read More

#News #Trending News

#Clinical trials #Covid-19 #Moderna #mRNA #Therapeutics

Moderna doses first patient with its IL-2 mRNA therapeutic candidate

Moderna has dosed the first patients in the Phase I study of mRNA-6231, the company’s mRNA-encoded IL-2, modified for the expansion of regulatory T cells. mRNA-6231 is Moderna’s first autoimmune candidate to enter the clinic and its first subcutaneously administered therapeutic program. “The initiation of the Phase I study of… Read More

#News #Trending News

#Clinical trials #Covid-19 #Drug design #Drug development #Drug discovery

ACRO releases toolkit to help advance decentralised clinical trials

The Association of Clinical Research Organizations (ACRO) released its DCT Toolkit, which lays out a vision for how decentralised clinical trials (DCTs) can be planned and executed now and in the future. When Covid-19 hit in March 2020, clinical trial participants were cut off from in-person clinical research visits. CROs… Read More

#News

#Biologics / Biotechnology #Biotechnology #Covid-19 #Life sciences #Public health

Europe’s emerging biotechs: Challenges, opportunities and funding

Listen to this article on the DDW Podcast: John Macdonald is Vice President, Venture & Financial Alliances at ICON. He examines the European biotech sector – its expertise and opportunities and potential for growth. By harnessing biological processes on a cellular and biomolecular level, biotech is benefitting industries as varied as… Read More

#Business & Investment #Covid-19 #Editor's Choice #Exclusive Content #Market Reports #News #Opinion

#AI / data analytics / healthtech / informatics #Automation / robotics #Biopharmaceuticals #Covid-19 #CRISPR #Drug discovery #Immunology / Virology & Vaccines #Lab automation #Moderna #Molecular Biology #Pfizer #Sequencing

What has 2020 taught us about lab automation?

Listen to this article on the DDW Podcast: Dr Patrick Courtney (SiLA consortium), Burkhard Schaefer (SiLA consortium/ASTM AnIML) and Oliver Peter, Senior Director, Senior Group Leader Biology Technologies and Lead Discovery, Biology, Idorsia Pharmaceuticals, look at the importance of automation in the face of global disease. As we write this, vaccines… Read More

#Covid-19 #Exclusive Content #News

#Covid-19 #Immunology / Virology & Vaccines #Innovation #Technology

Neutralising SARS-CoV-2 infection with shark VNAR antibodies

While the global vaccine roll-out continues, the role of therapeutic antibodies to combat Covid-19 should not be overlooked. Now researchers have identified a novel class of antibodies that appears to have an ability to neutralise the original strain of SARS-CoV-2 and be able to block some of the recent mutations… Read More

#Covid-19 #Editor's Choice #Intelligence #News #Opinion